203 related articles for article (PubMed ID: 20223458)
1. The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes.
Blum S; Vardi M; Levy NS; Miller-Lotan R; Levy AP
Atherosclerosis; 2010 Jul; 211(1):25-7. PubMed ID: 20223458
[No Abstract] [Full Text] [Related]
2. The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes.
Levy AP; Gerstein HC; Miller-Lotan R; Ratner R; McQueen M; Lonn E; Pogue J
Diabetes Care; 2004 Nov; 27(11):2767. PubMed ID: 15505023
[No Abstract] [Full Text] [Related]
3. Haptoglobin: a major susceptibility gene for diabetic cardiovascular disease.
Levy AP
Isr Med Assoc J; 2004 May; 6(5):308-10. PubMed ID: 15151377
[No Abstract] [Full Text] [Related]
4. Pharmacogenomics in prevention of diabetic cardiovascular disease: utilization of the haptoglobin genotype in determining benefit from vitamin E.
Levy AP; Blum S
Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1105-11. PubMed ID: 18035926
[TBL] [Abstract][Full Text] [Related]
5. Haptoglobin genotype and cardiovascular outcomes in diabetes mellitus - natural history of the disease and the effect of vitamin E treatment. Meta-analysis of the medical literature.
Vardi M; Blum S; Levy AP
Eur J Intern Med; 2012 Oct; 23(7):628-32. PubMed ID: 22939808
[TBL] [Abstract][Full Text] [Related]
6. Haptoglobin genotype and its role in diabetic cardiovascular disease.
Costacou T; Levy AP
J Cardiovasc Transl Res; 2012 Aug; 5(4):423-35. PubMed ID: 22447230
[TBL] [Abstract][Full Text] [Related]
7. The protean role of haptoglobin and haptoglobin genotypes on vascular complications in diabetes mellitus.
Dalan R; Liuh Ling G
Eur J Prev Cardiol; 2018 Sep; 25(14):1502-1519. PubMed ID: 29799294
[TBL] [Abstract][Full Text] [Related]
8. Patient selection and vitamin E treatment in diabetes mellitus.
Goldenstein H; Levy NS; Lipener YT; Levy AP
Expert Rev Cardiovasc Ther; 2013 Mar; 11(3):319-26. PubMed ID: 23469912
[TBL] [Abstract][Full Text] [Related]
9. The Role of Haptoglobin Polymorphism in Cardiovascular Disease in the Setting of Diabetes.
Somer S; Levy AP
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396615
[TBL] [Abstract][Full Text] [Related]
10. Vitamin E therapy results in a reduction in HDL function in individuals with diabetes and the haptoglobin 2-1 genotype.
Farbstein D; Blum S; Pollak M; Asaf R; Viener HL; Lache O; Asleh R; Miller-Lotan R; Barkay I; Star M; Schwartz A; Kalet-Littman S; Ozeri D; Vaya J; Tavori H; Vardi M; Laor A; Bucher SE; Anbinder Y; Moskovich D; Abbas N; Perry N; Levy Y; Levy AP
Atherosclerosis; 2011 Nov; 219(1):240-4. PubMed ID: 21722898
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenomic application of the haptoglobin genotype in the prevention of diabetic cardiovascular disease.
Blum S; Milman U; Shapira C; Levy AP
Pharmacogenomics; 2008 Aug; 9(8):989-91. PubMed ID: 18681772
[No Abstract] [Full Text] [Related]
12. Interaction Between the Haptoglobin Genotype and Vitamin E on Cardiovascular Disease in Diabetes.
Hochberg I; Berinstein EM; Milman U; Shapira C; Levy AP
Curr Diab Rep; 2017 Jun; 17(6):42. PubMed ID: 28451949
[TBL] [Abstract][Full Text] [Related]
13. Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype.
Blum S; Vardi M; Brown JB; Russell A; Milman U; Shapira C; Levy NS; Miller-Lotan R; Asleh R; Levy AP
Pharmacogenomics; 2010 May; 11(5):675-84. PubMed ID: 20415560
[TBL] [Abstract][Full Text] [Related]
14. Haptoglobin phenotype and coronary artery collaterals in diabetic patients.
Hochberg I; Roguin A; Nikolsky E; Chanderashekhar PV; Cohen S; Levy AP
Atherosclerosis; 2002 Apr; 161(2):441-6. PubMed ID: 11888529
[TBL] [Abstract][Full Text] [Related]
15. Dual therapy with statins and antioxidants is superior to statins alone in decreasing the risk of cardiovascular disease in a subgroup of middle-aged individuals with both diabetes mellitus and the haptoglobin 2-2 genotype.
Blum S; Milman U; Shapira C; Miller-Lotan R; Bennett L; Kostenko M; Landau M; Keidar S; Levy Y; Khemlin A; Radan A; Levy AP
Arterioscler Thromb Vasc Biol; 2008 Mar; 28(3):e18-20. PubMed ID: 18296583
[No Abstract] [Full Text] [Related]
16. Vitamin E in diabetes. Increased oxidative stress and its prevention as a strategy to prevent vascular complications?
Rösen P; Toeller M
Int J Vitam Nutr Res; 1999 May; 69(3):206-12. PubMed ID: 10389029
[No Abstract] [Full Text] [Related]
17. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy.
Lonn E; Yusuf S; Hoogwerf B; Pogue J; Yi Q; Zinman B; Bosch J; Dagenais G; Mann JF; Gerstein HC; ;
Diabetes Care; 2002 Nov; 25(11):1919-27. PubMed ID: 12401733
[TBL] [Abstract][Full Text] [Related]
18. Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes Prevention Evaluation.
Gerstein HC; Bosch J; Pogue J; Taylor DW; Zinman B; Yusuf S
Diabetes Care; 1996 Nov; 19(11):1225-8. PubMed ID: 8908384
[TBL] [Abstract][Full Text] [Related]
19. The effect of vitamin therapy on the progression of coronary artery atherosclerosis varies by haptoglobin type in postmenopausal women.
Levy AP; Friedenberg P; Lotan R; Ouyang P; Tripputi M; Higginson L; Cobb FR; Tardif JC; Bittner V; Howard BV
Diabetes Care; 2004 Apr; 27(4):925-30. PubMed ID: 15047650
[TBL] [Abstract][Full Text] [Related]
20. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial.
Sacco M; Pellegrini F; Roncaglioni MC; Avanzini F; Tognoni G; Nicolucci A;
Diabetes Care; 2003 Dec; 26(12):3264-72. PubMed ID: 14633812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
